Skip to main content
Anthony N. Vo

Anthony N. Vo

•Chief, Primary Care Health Care Group, Long Beach VA Medical Center
•HS Associate Clinical Professor, Without Salary, Step 4, UC Irvine Department of Medicine

Biography

Anthony N. Vo, M.D., is Chief of the Primary Care Health Care Group at the Long Beach VA Medical Center and HS Associate Clinical Professor in the Department of Medicine at the University of California, Irvine. He received his Doctor of Medicine from the University of California, Irvine in 1997 and completed his internal medicine residency at UCI Medical Center, where he served as Chief Resident. Vo has held his position as Chief of Primary Care since 2014, overseeing clinical operations, teaching internal medicine residents and students, and directing specialized clinics for dyslipidemia and hypertension.

Vo serves as Director of the Atherosclerosis Research Center at the Long Beach VA Medical Center, a position he has held since 2017 after serving as Associate Director from 2006 to 2017. In this capacity, he has served as principal investigator or co-principal investigator on numerous multicenter clinical trials examining cardiovascular outcomes, including the VA IMPACT trial investigating metformin in pre-diabetes, the PROMINENT study on pemafibrate for triglyceride reduction in diabetes, and the SELECT trial evaluating semaglutide effects on cardiovascular outcomes in obesity. His research portfolio spans trials of lipid-lowering therapies, antidiabetic medications, and cardiovascular interventions, with funding from the National Institutes of Health, the Department of Veterans Affairs, and pharmaceutical companies.

Vo holds administrative roles including Co-Chair of the Credentialing and Privileging Committee, Co-Chair of the Protected Peer Review Committee, and Chair of the PACT Steering Committee at the Long Beach VA Medical Center. He served as Acting Associate Program Director for the Ambulatory Care Section of the UCI Internal Medicine Residency Program from 2023 to 2024. Vo is a member of the American College of Physicians and the National Lipid Association, and he is board certified by the American Board of Internal Medicine.

Return to top

Education

  • MD, University of California, Irvine, 1997
  • BS in Biology, University of California, Irvine, 1992
Return to top

Distinctions

  • Graduate with Distinction, Department Of Veteran Affairs Leadership Development Institute, 2009
  • Resident of the Month, UCI Medical Center, 2000
  • Dean's Office Summer Research Fellowship, University of California, Irvine, 1994
  • Cum laude, University of California, Irvine, 1992
Return to top

Areas of Expertise

  • Cardiovascular Disease Prevention
  • Lipid Metabolism Disorders
  • Type 2 Diabetes Management
  • Nicotinic Acid Therapy
  • PCSK9 Inhibitor Trials
  • Hypertriglyceridemia Treatment
  • GLP-1 Receptor Agonists

Recent Publications

  • Brinton EA, Kashyap ML, Vo AN, Thakkar RB, Jiang P, Padley RJ, “Niacin Extended-Release Therapy in Phase III Clinical Trials is Associated with Relatively Low Rates of Drug Discontinuation due to Flushing and Treatment-Related Adverse Events A Pooled Analysis”, Am J Cardiovasc Drugs, vol. 11, no. 3, pp. 179-87, 2011.
  • Smith CS, Francovich C, Morris M, Hill W, Langois-Winkle F, Rupper R, Roth C, Wheeler S, Vo A, “Toward an ecological perspective of resident teaching clinic”, Adv Health Sci Educ Theory Pract, vol. 15, no. 5, pp. 771-8, 2010.
  • Insull W Jr, Basile JN, Vo AN, Jiang P, Thakkar R, Padley RJ, “Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME Study”, J Clin Lipidol, vol. 3, no. 2, pp. 109-18, 2009.
  • Kamana VS, Vo A, Kashyap ML, “Nicotinic acid: recent developments”, Current Opinion in Cardiology, vol. 23, no. 4, pp. 393-8, 2008.
  • Vo AN, Kashyap ML, “Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders”, Expert Rev Cardiovasc Ther, vol. 6, no. 10, pp. 1303-10, 2008.
  • Moon YSK, Juzba M, Gray DR, Vo A, “Cost-Effectiveness of Simvastatin/Ezetimibe 40mg/10mg Whole Tablet versus Simvastatin/Ezetimibe 80mg/10mg Half-Tablet (Simvastatin/Ezetimibe 40mg/5mg)”, 2007. Presented at 42nd American Society of Health-System Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 4, 2007.
  • Smith CS, Morris M, Hill W, Francovich C, McMullin J, Christiano J, Chavez L, Roth C, Vo A, Wheeler S, Milne C, “Testing the Exportability of a Tool for Detecting Operational Problems in VA Teaching Clinics”, J Gen Intern Med, vol. 21, no. 2, pp. 152-7, 2006.
  • Wong ND, Kouwabunpat D, Vo AN, Detrano RC, Eisenberg H, Goel M, Tobis JM, “Coronary Calcium and Atherosclerosis in Asymptomatic Men and Women” (opens in new tab), American Heart Journal, vol. 127, no. 2, pp. 422-430, 1994.
  • Wong ND, Vo AN, Abrahamson D, Tobis JM, Eisenberg H, Detrano RC, “Detection of Coronary Calcium by Ultrafast Computed Tomography and Its Relation to Clinical Evidence of Coronary Artery Disease” (opens in new tab), American Journal of Cardiology, vol. 73, pp. 223-227, 1994.
  • Mahaisavariya P, Detrano RC, Kang K, Garner D, Vo AN, Giorgiu D, Molloi S, Brundage BH, “Quantification of in vitro Coronary Artery Calcium Using Ultrafast Computed Tomography” (opens in new tab), Catherterization and Cardiovascular Diagnosis, vol. 32, no. 4, pp. 387-393, 1994.
  • Morris GSD, Vo AN, Bassin S, Savaglio D, Wong ND, “Prevalence and Sociobehavioral Correlates of Tobacco Use Among Hispanic Children: The Tobacco Resistance Activity Program”, Journal of School Health, vol. 63, no. 9, pp. 391-396, 1993.
Return to top

Contact Information

Email: avo@uci.edu

Phone: (714) 456-5109

Address: 5901 E. 7th Street, Long Beach, CA, Irvine, CA 92868

Return to top

This profile was created with the help of AI.

Last updated on 3/11/2026.